Search Results Search Sort by RelevanceMost Recent Medicine and Society Nov 2004 Gatekeeping and the FDA's Role in Human Subjects Protection Daniel Carpenter, PhD The FDA bears the responsibility to monitor clinical trials and protect human subjects from harm. Virtual Mentor. 2004;6(11):512-514. doi: 10.1001/virtualmentor.2004.6.11.msoc1-0411. Policy Forum Nov 2004 Genetic Samples and Genetic Philanthropy Michael E. Berens, PhD and Gary E. Marchant, PhD, JD Genetic research is threatened by lack of samples, and public policy should be developed to encourage public participation. Virtual Mentor. 2004;6(11):509-511. doi: 10.1001/virtualmentor.2004.6.11.pfor2-0411. In the Literature Nov 2004 Determining Research through Underdetermined Treatment Abraham P. Schwab, PhD Paul Miller and Charles Weijer defend the concept of equipoise in medical research in a recent journal article. Virtual Mentor. 2004;6(11):488-489. doi: 10.1001/virtualmentor.2004.6.11.jdsc1-0411. Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 2 Norman C. Fost, MD, MPH Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):300-301. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407. Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 3 Gary A. Green, MD Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):301-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407. Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 1 Stephen L. Brotherton, MD Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):298-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407. Viewpoint Aug 2004 Cosmetic Neurology: For Physicians the Future is Now Anjan Chatterjee, MD Medications for brain enhancement raise many ethical concerns regarding the roles of personal autonomy and responsibility. Virtual Mentor. 2004;6(8):367-371. doi: 10.1001/virtualmentor.2004.6.8.oped1-0408. Medicine and Society Oct 2004 Television on the Cutting Edge: Cosmetic Surgery Goes Prime-Time Leigh Turner, PhD Reality television programs that focus on cosmetic surgery show misguided viewers that such procedures are the key to emotional health and well-being. Virtual Mentor. 2004;6(10):462-464. doi: 10.1001/virtualmentor.2004.6.10.msoc1-0410. Case and Commentary Nov 2004 Clinical Trials and End-of-Life Decision Making, Commentary 2 Lucy Godley, MD, PhD Physicians can help oncology patients decide whether to focus on aggressive chemotherapy or less aggressive comfort measures for end-of-life care. Virtual Mentor. 2004;6(11):479-481. doi: 10.1001/virtualmentor.2004.6.11.ccas1-0411. Case and Commentary Nov 2004 Clinical Trials and End-of-Life Decision Making, Commentary 1 David S. Alberts, MD Physicians can help oncology patients decide whether to focus on aggressive chemotherapy or less aggressive comfort measures for end-of-life care. Virtual Mentor. 2004;6(11):477-479. doi: 10.1001/virtualmentor.2004.6.11.ccas1-0411. Pagination First page « First Previous page ‹ Previous … Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Current page 20 Page 21 Next page Next › Last page Last »
Medicine and Society Nov 2004 Gatekeeping and the FDA's Role in Human Subjects Protection Daniel Carpenter, PhD The FDA bears the responsibility to monitor clinical trials and protect human subjects from harm. Virtual Mentor. 2004;6(11):512-514. doi: 10.1001/virtualmentor.2004.6.11.msoc1-0411.
Policy Forum Nov 2004 Genetic Samples and Genetic Philanthropy Michael E. Berens, PhD and Gary E. Marchant, PhD, JD Genetic research is threatened by lack of samples, and public policy should be developed to encourage public participation. Virtual Mentor. 2004;6(11):509-511. doi: 10.1001/virtualmentor.2004.6.11.pfor2-0411.
In the Literature Nov 2004 Determining Research through Underdetermined Treatment Abraham P. Schwab, PhD Paul Miller and Charles Weijer defend the concept of equipoise in medical research in a recent journal article. Virtual Mentor. 2004;6(11):488-489. doi: 10.1001/virtualmentor.2004.6.11.jdsc1-0411.
Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 2 Norman C. Fost, MD, MPH Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):300-301. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407.
Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 3 Gary A. Green, MD Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):301-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407.
Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 1 Stephen L. Brotherton, MD Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):298-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407.
Viewpoint Aug 2004 Cosmetic Neurology: For Physicians the Future is Now Anjan Chatterjee, MD Medications for brain enhancement raise many ethical concerns regarding the roles of personal autonomy and responsibility. Virtual Mentor. 2004;6(8):367-371. doi: 10.1001/virtualmentor.2004.6.8.oped1-0408.
Medicine and Society Oct 2004 Television on the Cutting Edge: Cosmetic Surgery Goes Prime-Time Leigh Turner, PhD Reality television programs that focus on cosmetic surgery show misguided viewers that such procedures are the key to emotional health and well-being. Virtual Mentor. 2004;6(10):462-464. doi: 10.1001/virtualmentor.2004.6.10.msoc1-0410.
Case and Commentary Nov 2004 Clinical Trials and End-of-Life Decision Making, Commentary 2 Lucy Godley, MD, PhD Physicians can help oncology patients decide whether to focus on aggressive chemotherapy or less aggressive comfort measures for end-of-life care. Virtual Mentor. 2004;6(11):479-481. doi: 10.1001/virtualmentor.2004.6.11.ccas1-0411.
Case and Commentary Nov 2004 Clinical Trials and End-of-Life Decision Making, Commentary 1 David S. Alberts, MD Physicians can help oncology patients decide whether to focus on aggressive chemotherapy or less aggressive comfort measures for end-of-life care. Virtual Mentor. 2004;6(11):477-479. doi: 10.1001/virtualmentor.2004.6.11.ccas1-0411.